Wyeth

Other

American Home Products Corporation

Scott Christian Mayer

Eric Gould Gundersen

Robert E McDevitt

Hassan Mahmoud Elokdah

Alan Howard Katz

David LeRoy Crandall

Boyd Lynn Harrison

John Anthony Butera

Craig E Caufield

Anthony Frank Kreft

Alexander Greenfield

Joseph R Lennox

George Diamantidis

Lisa Marie Havran

Molly Hoke

Derek Cecil Cole

Minsheng Zhang

Russell Graceffa

Paul Jeffrey Dollings

Lynn Resnick

Rocco John Galante

Tingzhong Wang

Geraldine Ruth McFarlane

Arie Zask

Semiramis Ayral-Kaloustian

Thomas Joseph Caggiano

Dennis Michael Kubrak

Middleton Brawner Floyd

Hwei-Ru Tsou

Joshua Aaron Kaplan

Xiaoxiang Liu

Koi Morris

Kristina Martha Kutterer

Charles William Mann

Annette L Banker

Russell F Graceffa

Gary Harold Birnberg

Zhilian Tang

Diane Barbara Hauze

Ramaswamy Nilakantan

Alexander Michael Porte

Tritin Tran

Mercy Adufa Otteng

Marvin Reich

David Leroy Crandall

Compounds of Formula (I), are provided where T is CHO, COR, or C(OH)RR; Rand Rare hydrogen, optionally substituted lower alkyl, CF, optionally substituted alkenyl, or optionally substituted alkynyl; Ris hydrogen or optionally substituted lower alkyl; Ris (CF)alkyl, (CF)(substitutedalkyl), (CF)alkylphenyl, (CF)alkyl(substitutedphenyl), or (F)cycloalkyl; n=1-3; Ris hydrogen, halogen, CF, diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CRor N where at least one of W, Y or Z are C; Ris hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO, or NR; Ris hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and Ris lower alkyl, CF, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

This invention provides compounds of Formula (I), having the structure 

[object Object]

This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R, R, R, and Rare each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; Ris H, alkyl, perfluoroalkyl, aryl optionally substituted with R, alkanoyl, aroyl optionally substituted with R; Ris H, alkyl, alkylaryl, benzyl optionally substituted with R, alkanoyl, aroyl optionally substituted with R; Ris H, alkyl, alkylaryl, aryl optionally substituted with R; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SOH, POH, tetronic acid, etc.; Ris H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.

Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)

A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R-Rare defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors

Compounds of Formula (I), are provided where T is CHO, COR, or C(OH)RR; Rand Rare hydrogen, optionally substituted lower alkyl, CF, optionally substituted alkenyl, or optionally substituted alkynyl; Ris hydrogen or optionally substituted lower alkyl; Ris (CF)alkyl, (CF)(substituted alkyl), (CF)alkylphenyl, (CF)alkyl(substituted phenyl), or (F)cycloalkyl; n=1-3; Ris hydrogen, halogen, CF, diene fused to Y when Y&#x2550;C, or substituted diene fused to Y when Y&#x2550;C; W, Y and Z are C, CRor N where at least one of W, Y or Z are C; Ris hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO, or NR; Ris hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and Ris lower alkyl, CF, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R, R, R, R, R, R, R, W, Y, and Z are defined herein; or a pharmaceutically acceptable salt thereof.

Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation

The present invention relates generally to substituted heteroaryl benzofuran acids and methods of using them.

Substituted heteroaryl benzofuran acids

Compounds of Formula (I), are provided where T is CHO, CON, or C(OH)RR; Rand Rare hydrogen, optionally substituted lower alkyl, CF, optionally substituted alkenyl, or optionally substituted alkynyl; Ris hydrogen or optionally substituted lower alkyl; Ris (CF)alkyl, (CF)(substitutedalkyl), (CF)alkylphenyl, (CF)alkyl(substitutedphenyl), or (F)cycloalkyl; n=1-3; Ris hydrogen, halogen, CF, diene fused to Y when Y&#x2550;C, or substituted diene fused to Y when Y&#x2550;C; W, Y and Z are C, CRor N where at least one of W, Y or Z are C; Ris hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO, or NR; Ris hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and Ris lower alkyl, CF, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure 

This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein 

Benzyllactobionamides as inhibitors of smooth muscle cell proliferation

This invention provides compounds of Formula I having the structureor a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia

This invention provides PAI-1 inhibiting compounds of Formula I:wherein: R, R, R, and Rare each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; Ris H, alkyl, perfluoroalkyl, aryl optionally substituted with R, alkanoyl, aroyl optionally substituted with R; Ris H, alkyl, alkylaryl, benzyl optionally substituted with R, alkanoyl, aroyl optionally substituted with R; Ris H, alkyl, alkylaryl, aryl optionally substituted with R; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SOH, POH, tetronic acid, etc.; Ris H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.

Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1)

This invention provides compounds of Formula I having the structurewherein:

Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia

Growing community of inventors

Bridgewater, NJ, United States of America

Scott Christian Mayer